Adial Pharmaceuticals (ADIL) investor relations material

Executive summary

• Completed acquisition of Azora Therapeutics, shifting focus to inflammatory diseases, especially ulcerative colitis, with AT177 as the lead program.

• Raised $24.3M in net proceeds from a private placement, with potential for an additional $32.4M upon milestone warrant exercises.

• Company remains pre-revenue, with no products approved for sale and ongoing operating losses.

Financial highlights

• Net loss of $52.0M for Q2 2026, compared to $2.0M in Q2 2025, driven by a $46.2M acquired in-process R&D expense from the Azora acquisition.

• Operating expenses rose to $52.0M in Q2 2026 from $1.9M in Q2 2025, mainly due to the acquisition.

• Cash and cash equivalents were $28.7M as of June 30, 2026.

• Accumulated deficit reached $144.0M as of June 30, 2026.

Outlook and guidance

• Current cash is expected to fund operations into the second half of 2027, but not sufficient for planned Phase 1b clinical trials without additional financing.

• IND filing for AT177 planned for Q2 2027, with Phase 1a trial initiation in H2 2027 and proof-of-concept readout in H1 2028.

• Additional $32.4M could be raised if milestone warrants are exercised, which would fund the planned Phase 1b study.